Ontario Teachers Pension Plan Board Reduces Position in Hologic, Inc. (NASDAQ:HOLX)

Ontario Teachers Pension Plan Board lowered its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 62.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,637 shares of the medical equipment provider's stock after selling 35,343 shares during the period. Ontario Teachers Pension Plan Board's holdings in Hologic were worth $1,763,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in Hologic during the 2nd quarter worth about $25,000. Wolff Wiese Magana LLC bought a new position in Hologic in the third quarter worth approximately $25,000. iA Global Asset Management Inc. bought a new position in shares of Hologic in the first quarter valued at $37,000. Sunbelt Securities Inc. bought a new position in Hologic in the 2nd quarter valued at about $37,000. Finally, First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Up 1.0 %

Shares of HOLX stock traded up $0.80 during trading hours on Thursday, reaching $78.84. The company's stock had a trading volume of 355,543 shares, compared to its average volume of 1,584,349. The firm's fifty day simple moving average is $80.52 and its 200 day simple moving average is $78.30. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The stock has a market capitalization of $18.31 billion, a P/E ratio of 23.44, a P/E/G ratio of 2.48 and a beta of 0.98. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the firm posted $0.89 EPS. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. Equities research analysts expect that Hologic, Inc. will post 4.27 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their target price on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Tuesday, November 5th. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Finally, Citigroup downgraded Hologic from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.